Date: 2015-09-29
Type of information: Series B financing round
Company: Apitope (UK)
Investors: Wales Life Sciences Fund (UK) Vesalius Biocapital (Luxembourg) LRM (Belgium) PMV (Belgium) Wyvern (UK)
Amount: €12 million
Funding type: series B financing round
Planned used: The funds will enable Apitope to progress the clinical development of its pipeline which includes therapies for Factor VIII intolerance in hemophilia A patients and Graves’ disease. Apitope, whose first product candidate, ATX-MS-1467/M2736, is licensed to Merck Serono, will now progress its remaining portfolio of product candidates developed with its proprietary platform technology. Apitope’s lead product candidate, ATX-F8-117, has recently received orphan designations in both Europe and USA and targets hemophillia A. Apitope will also relocate its UK headquarters to Wales.
Others: * On September 29, 2015, Apitope, a drug discovery and development company focused on treating the underlying cause of autoimmune diseases, announced it has successfully raised €12 million in a Series B financing. The round was led by new investor Wales Life Sciences Fund. Current investors Vesalius Biocapital, LRM, PMV and Wyvern also
participated in the round. Existing shareholders include the Wellcome Trust. Brenig Preest, Wales Life Sciences Fund, will join the Apitope board.
Therapeutic area: Autoimmune diseases - Rare diseases - Hematological diseases - Genetic diseases
